In the immune-associated liver disease, more evidence is needed f

In the immune-associated liver disease, more evidence is needed for etiology clarification and treatment before transplantation.

Presenting Author: MOHAMMADREZA ABDOLLAHI Additional PXD101 cost Authors: MOHAMMADHOSSEIN SOMI Corresponding Author: MOHAMMADREZA ABDOLLAHI Affiliations: Young Researchers and Elite Club, Tabriz Branch, Islamic Azad University; Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences Objective: Autoimmune hepatitis (AIH) is an unresolving inflammation of the liver of unknown cause. It is characterized by the presence of interface hepatitis and portal plasma cell infiltration on histologic examination, hypergammaglobulinemia, and autoantibodies. One of widely used criteria for diagnosis is International Autoimmune Hepatitis Group BGJ398 (IAHG) recommendation. This study aimed at evaluating the clinical and paraclinical characteristics of AIH, comparing them with IAHG criteria. Methods: Sixty consecutive patients with AIH recuirted from university clinic in Tabriz University of medical science, Tabriz, Iran from Jan-2011 to Dec-2011. Patients were evaluated by reviewing demographic, physical examination and complete blood count (CBC). Serological and biochemical evaluation were done and the frequency of autoantibodies like antinuclear antibody (ANA), anti-smooth muscle antibody (ASMA), anti-liver-kidney microsomal

antibody (ALKM-1) type 1 and perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) were evaluated. Liver biopsy was done for all of the patients for diagnosing of the AIH. We used both comprehensive and simplified diagnostic scoring system for autoimmune hepatitis in this study. Results: Out of Sixty patients, 40 females, with the mean age of 39.45 ± 17.50 years, all enrolled patients were treated with prednisone and azathioprine. Percentile distribution of the study population into definite and probable did not change after the treatment. The most common sign and symptoms in descending order were fatigue

(100%), icter (66.7%), abdominal discomfort (33.3%), abdominal distension (28.3%), dark urine (23.3%), edema (23.3%), haematemesis (20.0%), pruritus (20.0%), melena (11.7%) and pale stool (10.0%). ALKM-1, P-ANCA, ANA and ASMA were positive in 71.4%, 66.7%, 42.4% and 19.4% cases, respectively. Due Erlotinib ic50 to paraclinical study findings, portal hypertensive gastropathy (45.0%), esophageal varices (41.7%) and cirrhosis (40.0%) were the most complications of autoimmune hepatitis in patients and there was not any evidence of primary sclerosing cholangitis, ulcerative colitis and overlap syndrome in these patients. According to IAHG, 80.0% of cases had definite diagnosis, 15.0% of cases had probable diagnosis and 5.0% of cases no AIH. Percentile distribution of the study population into definite, probable and no AIH did not changed after using simplified diagnostic scoring system for autoimmune hepatitis.

Comments are closed.